We also observed consistent results with clinical samples and public scRNA‐seq data from malignant melanoma patients and propose HPK1 upregulation as an evasion mechanism of NK cell surveillance by metastatic cancer cells and HPK1 as a druggable target for NK cell‐based cancer immunotherapy. Here, MAP4K1 is linked to melanoma.